Comparative efficacy of iBGStar™ glucose meter vs. traditional glucose monitoring in improving metabolic control and compliance towards self-monitoring of blood glucose in young patients with type 1 diabetes

Introduction. It is known that Type 1 diabetes is particularly hard to control by adolescents and young adults. In this population, the mean values of glycosylated hemoglobin far exceed the recommended targets in a large majority of patients. Moreover, a major issue is compliance, both in self-monitoring of blood glucose at home and at insulin treatment

Aims. The iNewTrend study has been designed to assess whether in a type 1 diabetes population aged 14-24 y.o., not compliants with self-monitoring blood glucose and not well controlled from a metabolic point of view, the use of technology (i.e. a next-generation blood glucose meter – iBGStar – linked with a smartphone) could improve adherence to treatment, clinical results and acceptance of the disease

Type of study. Randomized, controlled parallel group (1: 1), multi-center study

Population. 181 patients with type 1 diabetes treated with multiple injections of insulin, HbA1c> 8.0%, not compliants with home self-monitoring of blood glucose (<30% of the measurements prescribed by a doctor)

Centers. 21 Italian diabetes centers

Promoter. Sanofi SpA, Italy

Funding. Sanofi SpA, Italy

Status. Study completed

Bibliography:

  1. Di Bartolo P, Nicolucci A, Cherubini V, Iafusco D, Scardapane M, Rossi MC. Young patients with type 1 diabetes poorly controlled and poorly compliant with self-monitoring of blood glucose: can technology help? Results of the i-NewTrend randomized clinical trial. Acta Diabetol 2017; 54: 393-402.